← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT07290595

Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Post Operative Analgesia
Sponsor Sahiwal medical college sahiwal
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 66
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2025-01-13
Completion 2026-02-12
Interventions
Ropivacaine + DexmedetomidineRopivacaine + dexamethasone

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To compare the efficacy of dexmedetomidine and dexamethasone as an adjuvant to 0.5%ropivacaine on onset of ultrasound guided supraclavicular brachial plexus block in patients undergoing upper limb surgeries. Ropivacaine hydrochloride, a long acting local anesthetic, is commonly used for supraclavicular block owing to its favorable safety profile especially in terms of minimal cardiotoxicity and less motor block. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist, enhances the quality of supraclavicular block by providing sedation and analgesia while potentially prolonging the duration of block through hyperpolarization of nerve fibers. While, Dexamethasone, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, prolongs duration of analgesia by reducing perineural inflammation and inhibiting nociceptive signal transmission. Supraclavicular brachial plexus block offers dense anesthesia for surgical procedures at or distal to the elbow with relatively high success rate, once described as "spinal of the arm". Moreover, supraclavicular brachial plexus block is an excellent alternative to general anesthesia in upper limb surgeries.

Eligibility Criteria

Inclusion Criteria * Patients scheduled for upper limb surgery below mid-humerus level * Patients aged 18 to 70 years * Patients with ASA class I, II and III * Male and non-pregnant females Exclusion Criteria * Patients refusal * Patients with pre-existing peripheral neuropathy of the upper limb * Patients with the Infection at block site * Patients with history of ischemic heart disease * Patients with bleeding disorder or deranged coagulation profile * Patients with known history of allergy to local anaesthetic or any other drugs used

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}